Sirolimus in metatastic renal cell carcinoma.
Brugarolas
James
J
Department of Internal Medicine (Oncology Division), Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lotan
Yair
Y
Watumull
Lori
L
Kabbani
Wareef
W
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001707:Biopsy, Needle; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy; D010535:Laparoscopy / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D010166:Palliative Care; D011788:Quality of Life; D018570:Risk Assessment; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D020123:Sirolimus